PHASE II STUDY OF PEMBROLIZUMAB PLUS SURVAXM FOR GLIOBLASTOMA AT FIRST RECURRENCE

被引：0
|
作者：
Ahluwalia, Manmeet [1 ]
Peereboom, David [1 ]
Rauf, Yasmeen [2 ]
Schilero, Cathy [1 ]
Ciolfi, Marci [1 ]
Ciesielski, Michael [3 ]
Fenstermaker, Robert [4 ]
机构：
[1] Cleveland Clin, Main Campus, Cleveland, OH 44106 USA
[2] Cleveland Clin, Dublin, OH USA
[3] Roswell Pk, Buffalo, NY USA
[4] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
来源：
NEURO-ONCOLOGY | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CTIM-10
引用
收藏
页码：34 / 35
页数：3
相关论文
共 50 条
  • [21] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [22] A RANDOMIZED PHASE 2B STUDY OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)
    Ahluwalia, M. S.
    Ciesielski, M.
    Abad, A.
    Reardon, D.
    Aiken, R.
    Barbaro, M.
    Sinicrope, K.
    Peereboom, D. M.
    Odia, Y.
    Brenner, A.
    Venur, V.
    Butowski, N.
    Belal, A.
    Qiu, J.
    Ozair, A.
    Khosla, A. A.
    Schilero, C.
    Figel, S.
    Casucci, D.
    Mechtler, L.
    Fenstermaker, R.
    NEURO-ONCOLOGY, 2023, 25
  • [23] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [24] Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma.
    He, Aiwu Ruth
    Weinberg, Benjamin Adam
    Noel, Marcus Smith
    Milic, Violeta P.
    Prins, Petra
    Wang, Hongkun
    Hartley, Marion L.
    Marshall, John
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first line therapy
    Cohen, Deirdre Jill
    Lee, Jonathan W.
    Becker, Daniel Jacob
    Siolas, Despina
    Beri, Nina
    Ryan, Theresa
    Kozuch, Peter
    Yu, Shun
    Levinson, Benjamin A.
    Goldberg, Judith D.
    Leichman, Lawrence P.
    Oberstein, Paul Eliezer
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Cloughesy, Tim
    Finocchiaro, Gaetano
    Belda-Iniesta, Cristobel
    Recht, Lawrence
    Brandes, Alba A.
    Pineda, Estela
    Mikkelsen, Tom
    Chinot, Olivier
    Balana, Carmen
    Macdonald, David
    Westphal, Manfred
    Hopkins, Kirsten
    Weller, Michael
    Bruey, Jean-Marie
    Liu, Bo
    Verret, Wendy
    NEURO-ONCOLOGY, 2014, 16
  • [27] Phase II study for the evaluation of efficacy of pembrolizumab
    Naing, Aung
    Pant, Shubham
    Fu, Siqing
    Colen, Rivka
    Painter, Jeane
    Mcquinn, Lacey
    Mendoza, Tito
    Hess, Kenneth
    Meric-Bernstam, Funda
    Tannir, Nizar
    BJU INTERNATIONAL, 2016, 118 : 28 - 29
  • [28] Phase II study of pembrolizumab in leptomeningeal carcinomatosis
    Brastianos, Priscilla Kaliopi
    Prakadan, Sanjay
    Alvarez-Breckenridge, Christopher
    Lee, Eudocia Quant
    Tolaney, Sara M.
    Nayak, Lakshmi
    Lin, Nancy U.
    Navia, Andrew
    Bihun, Ivanna
    Chukwueke, Ugonma Nnenna
    Oh, Kevin S.
    White, Michael
    Gerstner, Elizabeth Robins
    Lawrence, Donald P.
    Cohen, Justine Vanessa
    Giobbie-Hurder, Anita
    Cahill, Daniel P.
    Shalek, Alex
    Carter, Scott L.
    Sullivan, Ryan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)
    Cortesi, L.
    Venturelli, M.
    Cortesi, G.
    Caggia, F.
    Toss, A.
    Barbieri, E.
    De Giorgi, U.
    Guarneri, V.
    Musolino, A.
    De Matteis, E.
    Zambelli, A.
    Bisagni, G.
    Dominici, M.
    ESMO OPEN, 2023, 8 (02)
  • [30] Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC).
    Shah, Manish A.
    Almhanna, Khaldoun
    Iqbal, Syma
    Thakkar, Prashant
    Schneider, Bryan J.
    Yantiss, Rhonda
    Wu, Yiru
    Futamura, Emma
    Port, Jeffrey L.
    Spinelli, Cathy
    Sarkar, Sandipto
    Christos, Paul J.
    Brar, Gagandeep
    Betel, Doron
    Sanfilippo, Nicholas J.
    Altorki, Nasser K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345